Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.

Autor: Perugino CA; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA., Wallace ZS; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Zack DJ; Xencor, Pasadena, CA, USA., Quinn SM; Clinical Development, Zenas BioPharma, Waltham, MA, USA., Poma A; Clinical Development, Zenas BioPharma, Waltham, MA, USA., Fernandes AD; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Foster P; Xencor, Pasadena, CA, USA., DeMattos S; Xencor, Pasadena, CA, USA., Burington B; Xencor, Pasadena, CA, USA., Liu H; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA., Allard-Chamard H; Division of Rheumatology, Faculté de médecine et des sciences de la santé de l'Université de Sherbrooke et Centre de Recherche Clinique Étienne-Le Bel, Sherbrooke, QC, Canada., Smith N; Penn State College of Medicine, Hershey, PA, USA., Kai X; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA., Xing K; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA., Pillai S; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA., Stone JH; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jhstone@mgh.harvard.edu.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2023 Aug; Vol. 5 (8), pp. e442-e450. Date of Electronic Publication: 2023 Jul 24.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.

Autor: Rugsley, T A, Davis, M D, Akunne, H C, Cooke, L W, Whetzel, S Z, MacKenzie, R G, Shih, Y H, van Leeuwen, D H, DeMattos, S B, Georgic, L M

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; August 1995, Vol. 274 Issue: 2 p898-911, 14p

Behavioral and neurochemical changes in the dopaminergic system after repeated cocaine administration.

Autor: Claye LH; College of Pharmacy, Florida A & M University, Tallahassee, USA., Akunne HC, Davis MD, DeMattos S, Soliman KF

Publikováno v: Molecular neurobiology [Mol Neurobiol] 1995 Aug-Dec; Vol. 11 (1-3), pp. 55-66.

Characterization of the human dopamine D3 receptor expressed in transfected cell lines.

Autor: MacKenzie RG; Parke-Davis, Department of Pharmacology, Ann Arbor, MI 48106., VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O'Malley KL

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 1994 Jan 01; Vol. 266 (1), pp. 79-85.